Europa Trial
General Public Heathcare Professionals Virtual Press Office

New Indication in CAD

EUROPA calendar
ACC 2006 - Posters
ESC 2005 - Symposium
ESC 2005 - Oral sessions
ESC 2005 - Posters
AHA 2004 - Oral Session
ESC 2004 - Hotline
ESC 2004 - Symposium
ACC 2004
ESC 2003

EUROPA study
EUROPA Results
ESC 2003 Hotline - video
Rationale for EUROPA
Rationale for Perindopril
Design & Organisation
EUROPA investigators
EUROPA collaborating centres
EUROPA Recruitment

EUROPA Slide Set
Rationale and Design
Clinical Implications

EUROPA publications

PERSUADE Publications


Background : Coronary Artery Disease
Home : Healthcare professionals : New Indication in Coronary Artery Disease
New Indication in Coronary Artery Disease

Perindopril new indication

The ACE inhibitor Perindopril received a positive opinion from the EMEA (European Medical Evaluation Agency) recommending the extension of its licence indication for the treatment of patients with stable coronary artery disease (CAD) to reduce the risk of cardiac events in patients with a history of MI and / or revascularisation. The FDA has now also approved a label extension for Perindopril for a similar indication in the US. This new indication is in addition to Perindopril's well-established position as an effective antihypertensive agent.

The EMEA gave the green light to approve the new indication for Perindopril based on the results of EUROPA (The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease), the landmark trial involving 12,218 patients with stable CAD and without heart failure which showed that Perindopril significantly cuts the risk of cardiovascular mortality and non-fatal MI by 20% compared to placebo (p=0.0003).1 In the EUROPA study, patient received 8 mg of Perindopril in addition to standard preventive therapy.

New EUROPA data

Further features of Perindopril's cardiovascular protective properties were confirmed by new data from EUROPA presented at this year's ESC meeting. In a subgroup of EUROPA patients (n=7,096) who had a precisely-measured left ventricular ejection fraction (mean LVEF=57%), Coversyl reduces the risk of CV death, non fatal MI and cardiac arrest by 16% (p<0.03). Additional analysis demonstrates that the beneficial effect of Perindopril 8 mg was independent of cardiovascular risk level, baseline blood pressure, concomitant treatments (betablockers, lipid lowering drugs) or history of previous revascularisation, reinforcing the specificity of EUROPA results in comparison with HOPE, ACTION and PEACE.2-4 "The results from the EUROPA trial have extremely important clinical implications and the new indication for Perindopril in CAD will help doctors improve prognosis in CAD patients, even in those with relatively low risk, beyond that achievable with existing standard therapy", points out Professor K Fox, M.D, Royal Brompton Hospital, London, UK and chairman of the EUROPA trial. "Perindopril therapy should be considered in addition to other preventive treatments, even in the absence of heart failure, marked reduction in LV function or risk factors for all CAD patients."

1. Fox KM; European trial on reduction of cardiac events with perindopril in stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery diseased: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8

2. Bertrand ME et al. Effects of Perindopril on long-term outcome of patients with coronary artery disease and preserved left ventricular function the EUROPA study. Poster. ESC 2005

3. Deckers JW et al. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Abstract n3663, ESC 2005

4. Ceconi C et al. Effect of perindopril in patients with stable coronary disease: results on inflammatory and thrombosis markers of the pertinent study. Abstract n3665, ESC 2005

This website is intended for an international audience. Drug related information may refer to unlicensed products or uses which may not be approved in your own country and you should therefore consult your local prescribing information.
This site is published and updated by the EUROPA study investigators. Site last updated March 21st 2006
To report a suspected side-effect with a Servier drug, please click here.
Terms of use - ©2005 EUROPA All rights reserved